I believe $JNJ, at approximately $63/share, is a good value with a margin of safety.
Johnson & Johnson ranks as the world's largest and most diverse health-care company. The company comprises three divisions: pharmaceutical, medical devices and diagnostics, and consumer. While the pharmaceutical division currently represents 35% of total sales, we expect patent losses to reduce this proportion to 30% over the next 10 years, with the remaining divisions picking up equal share.
(Source: Morningstar.com)
Johnson & Johnson ranks as the world's largest and most diverse health-care company. The company comprises three divisions: pharmaceutical, medical devices and diagnostics, and consumer. While the pharmaceutical division currently represents 35% of total sales, we expect patent losses to reduce this proportion to 30% over the next 10 years, with the remaining divisions picking up equal share.
(Source: Morningstar.com)
I estimated the firm's WACC at 8.94% using the Capital Asset Pricing Model and the company's recent SEC filings. ValuePro has an online baseline WACC calculator at http://www.valuepro.net/index.shtml. It calculates $JNJ's WACC at 6.81%. Factor in a margin of safety and go with the higher figure: 8.94%.
Recent free cash flows and noted growth rates:
Year | FCF $Millions |
2000 | 4917 |
2001 | 7133 |
2002 | 6077 |
2003 | 8333 |
2004 | 8956 |
2005 | 9245 |
2006 | 11510 |
2007 | 11939 |
2008 | 11906 |
2009 | 14206 |
TTM | 15579 |
Average Annual Growth: approx14%
CAGR: approx 13%
Internal Growth Rate: approx 8%
Sustainable Growth Rate: approx 17%
Consensus Forecast Industry 5-Year Growth: approx 10% per year
Consensus Forecast Company 5-Year Growth: approx 6% per year
CAGR: approx 13%
Internal Growth Rate: approx 8%
Sustainable Growth Rate: approx 17%
Consensus Forecast Industry 5-Year Growth: approx 10% per year
Consensus Forecast Company 5-Year Growth: approx 6% per year
Go with the forecast 5-year growth rate of 6% per year, and assume that after the next five years, the company achieves no growth or 0% growth per year forever; a harsh no growth assumption for $JNJ.
Discounted Cash Flow Valuation
Year | FCF $ Millions |
0 | 15579 |
1 | 16514 |
2 | 17505 |
3 | 18555 |
4 | 19668 |
5 | 20848 |
Terminal Value | 247194 |
The firm's future cash flows, discounted at a WACC of 8.94%, give a present value for the entire firm (Debt + Equity) of $232,913 million. If the firm's fair value of all debt is estimated at $13,431 million, then the fair value of the firm's equity could be $219,482 million.
$219,482 million / 2,750 million outstanding shares = $79.81 per share. A 20% margin of safety from here is approx $64 per share and $JNJ's current share price is approx $63. I consider $JNJ a good buy with a margin of safety for the long term.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
No comments:
Post a Comment